Your shopping cart is currently empty

EGFR-IN-171 is an epidermal growth factor receptor (EGFR) inhibitor with an IC50 value of 0.19 μM. It also inhibits vascular endothelial growth factor 2 (VEGFR-2), with an IC50 of 31.65 μM. EGFR-IN-171 can induce apoptosis and cause G2/M cell cycle arrest. This compound can be utilized in cancer research, particularly for liver cancer and breast cancer.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | EGFR-IN-171 is an epidermal growth factor receptor (EGFR) inhibitor with an IC50 value of 0.19 μM. It also inhibits vascular endothelial growth factor 2 (VEGFR-2), with an IC50 of 31.65 μM. EGFR-IN-171 can induce apoptosis and cause G2/M cell cycle arrest. This compound can be utilized in cancer research, particularly for liver cancer and breast cancer. |
| In vitro | EGFR-IN-171 (Compound 6b) exhibits cytotoxicity against HepG-2, MCF-7, and HCT-116 cells with IC50 values of 5.8, 3.91, and 7.97 μM, respectively. At a concentration of 3.91 μM for 24 hours, EGFR-IN-171 enhances apoptosis in MCF-7 cells and causes accumulation in the G2/M phase. Furthermore, it increases the levels of Bax and p53 while reducing Bcl-2 levels in MCF-7 cells. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.